As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

An obesity medicine physician writes that weight-loss drugs such as Ozempic have been getting a bad rap, almost as if those ...

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease seve ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

They're known to aid in blood sugar control and, now, weight loss — however, according to a sweeping new study, the popular ...